Tufts Center for Drug Development

Latest Headlines

Latest Headlines

Tufts: Billions wasted in pharma R&D despite new biz models

Pharma outfits have engineered all kinds of newfangled strategies to streamline aspects of drug R&D, yet many of these approaches fail to fix broken areas of development that cost companies billions of dollars, says Ken Kaitin, director of the Tufts Center for the Study of Drug Development.

Tufts: Cancer drugs win a speedier race to the FDA goal line

Anyone trying to explain the onrush of new cancer therapies in the pipeline should check out a new report from the Tufts Center for the Study of Drug Development, which found that cancer drugs have enjoyed faster approval times at the FDA than all other disease categories combined.

CNS drug developers face long stretch in the clinic, poor odds of success

The exodus of Big Pharma companies from the CNS drug development field has put a bright spotlight on the hurdles any developer faces when tackling a tricky disease like Alzheimer's.

Analysis: Grim stats on CNS drugs demand fresh approach to development

It's no secret that neuropsychiatric diseases like schizophrenia, depression and Alzheimer's present one of the toughest challenges to drug developers. Ken Kaitin and Christopher Milne at the Tufts

Report: Approval success rates higher for smaller firms

The top 10 pharmaceutical companies out of the world's top 50 have lower estimated overall clinical approval success rates than do smaller firms in that group, according to a report completed by the